Lavoltidine
Jump to navigation
Jump to search
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C19H29N5O2 |
Molar mass | 359.474 g·mol−1 |
3D model (JSmol) | |
|
Lavoltidine (INN,[1] USAN, BAN; previously known as loxtidine, code name AH-23,844) is a highly potent and selective H2 receptor antagonist which was under development by Glaxo Wellcome (now GlaxoSmithKline)[2] as a treatment for gastroesophageal reflux disease but was discontinued due to the discovery that it produced gastric carcinoid tumors in rodents.[3][4]
See also
- H2 receptor antagonist
- Sufotidine (analogous sequence in which a sulfonyl group replaces the hydroxyl group)
References
- ^ "International Nonproprietary Names for Pharmaceutical Substances. Recommended International Nonproprietary Names (Rec. INN): List 30" (PDF). WHO Drug Information. World Health Organization. 4 (3): 7. 1990. Retrieved 12 January 2016.
- ^ "Drug Profile: Lavoltidine". AdisInsight. Springer International Publishing AG. Retrieved 12 January 2016.
- ^ Washington N (1991). Antacids and anti-reflux agents. Boca Raton: CRC Press. ISBN 0-8493-5444-7.
- ^ Dictionary of organic compounds. London: Chapman & Hall. 1996. ISBN 0-412-54090-8.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Drugs with non-standard legal status
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles containing unverified chemical infoboxes
- Abandoned drugs
- Primary alcohols
- Amines
- H2 receptor antagonists
- 1-Piperidinyl compounds
- Triazoles
- Phenol ethers